{"id":"NCT01961349","sponsor":"AstraZeneca","briefTitle":"Phase III Study of ICI35,868 (Diprivan) With and Without EES0000645/A (SDS) on Gastrointestinal Endoscopy","officialTitle":"A Multi-centre, Double-blind, Randomised, Parallel-group, Placebo-controlled, Phase III Confirmatory Study to Assess Efficacy and Safety of the Moderate Sedation of ICI35,868 With and Without EES0000645/A on Gastrointestinal Endoscopy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-10","primaryCompletion":"2014-03","completion":"2014-03","firstPosted":"2013-10-11","resultsPosted":"2015-11-27","lastUpdate":"2015-11-27"},"enrollment":279,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Sedation to be Moderate for a Diagnostic Gastrointestinal Endoscopy and Gastrointestinal Endoscopic Polypectomy"],"interventions":[{"type":"DRUG","name":"Intralipid","otherNames":[]},{"type":"DRUG","name":"ICI35,868 (Diprivan)","otherNames":[]},{"type":"DRUG","name":"ICI35,868 (Diprivan) + EES0000645/A (SDS)","otherNames":[]}],"arms":[{"label":"Group 1","type":"PLACEBO_COMPARATOR"},{"label":"Group 2","type":"ACTIVE_COMPARATOR"},{"label":"Group 3","type":"ACTIVE_COMPARATOR"}],"summary":"This study is designed as a multi-centre, randomised, parallel-group, placebo-controlled, phase III confirmatory study. The study will be partially double-blinded: the comparison between Group 1 (placebo group) and Group 2 (ICI35,868 without EES0000645/A) will be carried out in double-blind, but the comparison between Group 1 (placebo group) and Group 3 (ICI35,868 with EES0000645/A) will be carried out in single-blind.\n\nThe efficacy and safety of ICI35,868 with and without EES0000645/A for the sedation to be moderate for a diagnostic gastrointestinal endoscopy and gastrointestinal endoscopic polypectomy will be evaluated.","primaryOutcome":{"measure":"Achivement of Target Sedation","timeFrame":"from scope-in to scope-out","effectByArm":[{"arm":"Placebo","deltaMin":21.6,"sd":null},{"arm":"ICI35,868 Without EES0000645/A","deltaMin":88.1,"sd":null},{"arm":"ICI35,868 With EES0000645/A","deltaMin":94.5,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"},{"comp":"OG000 vs OG002","p":"<0.001"}]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":3,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":["http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=1892&filename=D0092C00002_CSR_Synopsis.pdf"]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":51},"commonTop":["Abdominal pain lower","blood urine present","disinhibition","sedation","oxygen saturation decreased"]}}